CYTK
Price
$40.52
Change
+$0.27 (+0.67%)
Updated
Apr 3 closing price
Capitalization
4.8B
27 days until earnings call
NGENF
Price
$2.27
Change
+$0.18 (+8.61%)
Updated
Apr 2 closing price
Capitalization
151.99M
Ad is loading...

CYTK vs NGENF

Header iconCYTK vs NGENF Comparison
Open Charts CYTK vs NGENFBanner chart's image
Cytokinetics
Price$40.52
Change+$0.27 (+0.67%)
Volume$2.74M
Capitalization4.8B
NervGen Pharma
Price$2.27
Change+$0.18 (+8.61%)
Volume$172.4K
Capitalization151.99M
CYTK vs NGENF Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. NGENF commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and NGENF is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CYTK: $40.52 vs. NGENF: $2.16)
Brand notoriety: CYTK and NGENF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 147% vs. NGENF: 210%
Market capitalization -- CYTK: $4.8B vs. NGENF: $151.99M
CYTK [@Biotechnology] is valued at $4.8B. NGENF’s [@Biotechnology] market capitalization is $151.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileNGENF’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NGENF’s FA Score: 0 green, 5 red.
According to our system of comparison, NGENF is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while NGENF’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 6 bearish.
  • NGENF’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CYTK and NGENF are a bad buy in the short-term.

Price Growth

CYTK (@Biotechnology) experienced а -5.75% price change this week, while NGENF (@Biotechnology) price change was +17.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

CYTK is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.8B) has a higher market cap than NGENF($152M). NGENF YTD gains are higher at: -0.917 vs. CYTK (-13.861). NGENF has higher annual earnings (EBITDA): -27.5M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. NGENF (21M). NGENF has less debt than CYTK: NGENF (129K) vs CYTK (789M). CYTK has higher revenues than NGENF: CYTK (18.5M) vs NGENF (0).
CYTKNGENFCYTK / NGENF
Capitalization4.8B152M3,157%
EBITDA-493.48M-27.5M1,794%
Gain YTD-13.861-0.9171,511%
P/E RatioN/AN/A-
Revenue18.5M0-
Total Cash1.08B21M5,124%
Total Debt789M129K611,628%
FUNDAMENTALS RATINGS
CYTK vs NGENF: Fundamental Ratings
CYTK
NGENF
OUTLOOK RATING
1..100
8322
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
6450
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8343
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGENF's Valuation (81) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's Profit vs Risk Rating (50) in the null industry is in the same range as CYTK (64) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's SMR Rating (100) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that NGENF’s stock grew similarly to CYTK’s over the last 12 months.

NGENF's Price Growth Rating (43) in the null industry is somewhat better than the same rating for CYTK (83) in the Biotechnology industry. This means that NGENF’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for NGENF (100) in the null industry. This means that CYTK’s stock grew significantly faster than NGENF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNGENF
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MMIN23.720.14
+0.62%
NYLI MacKay Muni Insured ETF
SYNB27.98N/A
N/A
Putnam BioRevolution ETF
VRP24.00-0.28
-1.15%
Invesco Variable Rate Preferred ETF
CLSE21.10-0.74
-3.39%
Convergence Long/Short Equity ETF
PEZ82.02-6.39
-7.23%
Invesco DW Consumer Cyclicals Momt ETF

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IDYA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+0.67%
IDYA - CYTK
45%
Loosely correlated
-4.77%
KRON - CYTK
43%
Loosely correlated
-4.31%
DARE - CYTK
42%
Loosely correlated
+0.69%
KRYS - CYTK
42%
Loosely correlated
-1.59%
TRDA - CYTK
41%
Loosely correlated
-8.86%
More

NGENF and

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-4.85%
CYTK - NGENF
25%
Poorly correlated
+0.67%
IBRX - NGENF
23%
Poorly correlated
-2.62%
TNFA - NGENF
22%
Poorly correlated
+0.02%
CARM - NGENF
22%
Poorly correlated
-13.55%
ATRA - NGENF
22%
Poorly correlated
-3.43%
More